Galecto Advances Phase 2b Study of GB0139 in Idiopathic Pulmonary Fibrosis Recruitment Remains on Track Despite COVID-19 Crisis
May 06, 2020 02:00 ET
|
Galecto, Inc.
Recruitment on track in international “GALACTIC-1” Phase 2b IPF studyOver 150 patients recruited to date with data readout expected in 2022Galecto continues to build strong portfolio in fibrosis and...
Galecto Presents GB0139 Preclinical and Clinical Data on Anti-Fibrotic Activity as Online Experimental Biology 2020 Poster
May 04, 2020 02:00 ET
|
Galecto, Inc.
GB0139 showed pharmacodynamic evidence with reduction of galectin-3Direct link to clinical results in IPF patients after 14 days treatmentLead compound being developed in Phase 2b trial, with readout...
Galecto Appoints Jonathan Freve as Chief Financial Officer
April 27, 2020 08:00 ET
|
Galecto, Inc.
COPENHAGEN, Denmark, April 27, 2020 (GLOBE NEWSWIRE) -- Galecto, Inc., a privately-held biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced...
Galecto Appoints Industry Leader Bertil Lindmark, MD, PhD, as Chief Medical Officer
February 03, 2020 04:00 ET
|
Galecto, Inc.
Dr. Lindmark brings broad R&D expertise, particularly in respiratory and inflammationAppointment reinforces Galecto’s ambition to be a global player following PharmAkea merger COPENHAGEN,...
Galecto and PharmAkea Merge to Create Strong Clinical-Stage Company Developing First-in-Class Therapeutics in Fibrosis and Cancer
January 07, 2020 01:30 ET
|
Galecto, Inc.
Clinical programs in IPF, NASH and cancerJoint entity to be named Galecto, Inc. SAN DIEGO and COPENHAGEN, Denmark, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Galecto, the leading developer of galectin...